Browse HTRA3

Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted Note=Secretion increased during decidualization of endometrial stromal cells.
Domain PF00219 Insulin-like growth factor binding protein
PF07648 Kazal-type serine protease inhibitor domain
PF13180 PDZ domain
Function

Serine protease that cleaves beta-casein/CSN2 as well as several extracellular matrix (ECM) proteoglycans such as decorin/DCN, biglycan/BGN and fibronectin/FN1. Inhibits signaling mediated by TGF-beta family proteins possibly indirectly by degradation of these ECM proteoglycans (By similarity). May act as a tumor suppressor. Negatively regulates, in vitro, trophoblast invasion during placental development and may be involved in the development of the placenta in vivo. May also have a role in ovarian development, granulosa cell differentiation and luteinization (PubMed:21321049, PubMed:22229724).

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0016049 cell growth
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0030509 BMP signaling pathway
GO:0030510 regulation of BMP signaling pathway
GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway
GO:0030514 negative regulation of BMP signaling pathway
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
Molecular Function GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0005520 insulin-like growth factor binding
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
GO:0019838 growth factor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HTRA3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HTRA3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HTRA3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.7720.00304
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.7250.13
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0510.337
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.1410.0531
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2310.459
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0230.642
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.010.988
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6680.607
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.8850.559
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3880.413
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.3390.119
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6110.00891
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HTRA3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HTRA3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HTRA3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HTRA3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HTRA3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HTRA3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HTRA3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHTRA3
NameHtrA serine peptidase 3
Aliases Prsp; pregnancy-related serine protease; high-temperature requirement factor A3; probable serine protease HT ......
Chromosomal Location4p16.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HTRA3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.